By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Clinical Research have been presented. According to news originating from Tempe, Arizona, by NewsRx correspondents, research stated, "Fungal infections are rare but major problems when they involve orthopaedic implants. Preferred treatment in North America is two-staged: resection and then delayed reconstruction, with local delivery of an antifungal between stages."
Our news journalists obtained a quote from the research from Arizona State University, "The effect of voriconazole, a hydrophobic antifungal, on local tissues and wound healing is unclear. We asked: (1) Is voriconazole cytotoxic to fibroblasts or osteoblasts at target concentrations for local delivery? And (2) if cytotoxic, can fibroblasts or osteoblasts resume proliferation after voriconazole is removed? We exposed 5000 fibroblasts or osteoblasts/well to voriconazole concentrations of 0, 1, 5, 10, 25, 100, 500, 1000, 5000, 10,000, and 20,000 mu g/mL (n = 4 wells/concentration) in 24-well plates. At 3 and 7 days, cell growth was assessed with alamarBlue(A ®) and light microscopy. After Day 7, exposure to voriconazole was stopped and incubation continued for 4 days in medium with no voriconazole. On Day 11, cell growth (recovery) was assessed with alamarBlue(A ®) and light microscopy. Increasing voriconazole concentration to more than 100 mu g/mL decreased osteoblast and fibroblast growth. Cell growth recovered after 7 days' exposure to 1000 mu g/mL or less. Voriconazole is cytotoxic to osteoblasts and fibroblasts, but cell growth recovers over 4 days after exposure to 1000 mu g/mL or less. Cytotoxicity seen from voriconazole to mouse osteoblasts and fibroblasts occurs at concentrations achievable clinically from local delivery."
According to the news editors, the research concluded: "It may be prudent to limit the dose of voriconazole in antibiotic-loaded bone cement."
For more information on this research see: Voriconazole Is Cytotoxic at Locally Delivered Concentrations: A Pilot Study. Clinical Orthopaedics and Related Research, 2013;471(10):3165-3170. Clinical Orthopaedics and Related Research can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Clinical Orthopaedics and Related Research - www.springerlink.com/content/0009-921x/)
The news correspondents report that additional information may be obtained from K. Schmidt, Arizona State University, Center Intervent Biomat, Tempe, AZ, United States. Additional authors for this research include A. McLaren, C. Pauken and R. McLemore (see also Clinical Research).
Keywords for this news article include: Tissue Engineering, Biomedical Engineering, Biomedical and Dental Materials, Biomedicine, Tempe, Arizona, Fibroblasts, Osteoblasts, Bone Cements, United States, Bioengineering, Clinical Research, Connective Tissue Cells, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC